Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study

Sacha I. Rothschild(University Hospital of Basel), Markus Borner(University of Bern), Miklos Pless(Ontario Institute for Cancer Research), Vera Bühler, Reinhard Zenhäusern, Roger von Moos(Kantonsspital Graubünden), Claudia Papet(Spital Limmattal), Antonello Calderoni(Varian Medical Systems (Switzerland)), Sandro Anchisi(Hôpital du Valais), Stefanie Pederiva(Kantonsspital Baden), Peter Moosmann(University of St.Gallen), Regina Woelky(Kantonsspital Frauenfeld), Răzvan Popescu(Hirslanden Klinik Aarau), Daniel Betticher, Marco Dressler(Hirslanden Klinik St. Anna), Daniel Rauch(Washington University in St. Louis)
Cancer Chemotherapy and Pharmacology
August 23, 2019
10.1007/s00280-019-03927-x
Cited by 8

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
|Journal of Clinical Oncology|2017|357